LEH Pharma Appoints Syneos Health as Global Clinical Development and Commercialization Solutions Provider

Source: LEH Pharma

LEH Pharma, a provider of ocular implants for macular disorders, announced the selection of Syneos Health, a fully integrated biopharmaceutical solutions organization, as its global clinical development and commercialization provider.

The primary aim of the strategic relationship is to accelerate the commercialization of LEH Pharma’s EyeMax lens, a patented product marketed internationally for the treatment of age-related macular degeneration (AMD). Through this relationship, LEH Pharma gains access to the industry’s only end-to-end biopharmaceutical solutions organization, including the industry’s largest Contract Commercial Organization (CCO) and a leading Contract Research Organization (CRO). Leveraging the company’s deep therapeutic and launch expertise, Syneos Health has helped to develop or commercialize 84% of novel new drugs approved by the FDA and 70% of products granted marketing and authorization by the European Medicine Agency (EMA) in a recent 5-year period.

Syneos Health’s Integrated Solutions Group (ISG) will oversee the commercialization of EyeMax. The ISG team will orchestrate Syneos Health’s vast clinical commercialization capabilities and talent, sharing data and synthesized insights to drive efficiencies and speed. This will include providing strategic guidance to LEH Pharma by leveraging the company’s clinical, Real World Evidence, market access, clinical affairs, marketing communications and regulatory capabilities. Syneos Health will also provide LEH Pharma with Medical Science Liaisons (MSL), through a dedicated team that will provide training and support services to the Company’s affiliated surgeons for the use of the EyeMax lens.

“We are delighted to enter into this relationship with Syneos Health. Their expertise and insight will be vital as we continue the commercial expansion of the EyeMax lens, which we believe has the potential to improve the quality of life of millions of AMD sufferers around the world whose needs are not adequately addressed,” Dr. Bobby Qureshi, Founder and CEO of LEH Pharma, said in a company news release.

Alistair Macdonald, Chief Executive Officer of Syneos Health, said: “Syneos Health offers forward-thinking biopharmaceutical companies a unique outsourcing model for comprehensive commercialization, designed to improve the likelihood of launch and market success. We are pleased to provide this approach to LEH Pharma, maximizing returns throughout the product lifecycle and expanding the availability of their much needed product to patients worldwide.”


Related Content